Profil
Christina Furebring is currently the Deputy Director at Atlas Therapeutics AB and A Bioscience Incentive AB. She is also the Chief Operations Officer at Strike Pharma AB since 2022.
Previously, she worked as the Senior Vice President-Preclinical Development at Alligator Bioscience AB. Dr. Furebring holds a doctorate degree from the University of Lund.
Postes actifs de Christina Furebring
| Sociétés | Poste | Début |
|---|---|---|
A Bioscience Incentive AB | Corporate Officer/Principal | - |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures antibodies drugs | Corporate Officer/Principal | - |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that engages in development of immunotherapeutic treatments | Directeur des opérations | 01/01/2022 |
Anciens postes connus de Christina Furebring
| Sociétés | Poste | Fin |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Corporate Officer/Principal | - |
Formation de Christina Furebring
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Alligator Bioscience AB
Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures antibodies drugs | Health Technology |
A Bioscience Incentive AB | |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that engages in development of immunotherapeutic treatments | Commercial Services |
















